Full history for every metric is available with a Kvantra account
Akouos, Inc. (AKUS)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -87 | -92 | |||||
| Net profit | $m | - | - | -6 | -26 | -49 | -87 | -93 |
| EPS reported | $ | -4.94 | -2.64 | |||||
| Operating cashflow per share | $ | -3.63 | -3.63 | |||||
| Capex per share | $ | 0.51 | 0.51 | |||||
| FCF per share | $ | -4.15 | -4.15 | |||||
| Free cash flow | $m | -73 | -87 | |||||
| Net debt | $m | -203 | -169 | |||||
| Book value equity | $m | 234 | 181 | |||||
| Book value per share | $ | 13.31 | 4.90 | |||||
| Number of shares | m | 17.55 | 36.91 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.64 | 2.71 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -2.05 | -5.66 | |||||
| EV/EBITDA LTM | x | -0.68 | -3.67 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -58.10% | -37.16% | |||||
| FCF Yield | % | -48.77% | -17.66% | |||||
| Quality | ||||||||
| ROE | % | -37.09% | -31.85% | |||||
| ROIC | % | -33.00% | -33.00% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.51 | -2.45 | |||||
| Net Debt/EBITDA | x | 1.12 | 1.12 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -136.39% | -34.52% | |||||
| Net debt/Equity | x | -0.87 | -0.94 | |||||
| Gross debt/equity | x | 0.12 | 0.20 | |||||
Company overview
Akouos, Inc. is a company dedicated to precise genetic medicine, developing gene therapies with the aim of restoring, enhancing, and safeguarding individuals' natural auditory function. Central to its strategy is an advanced genetic medicine platform, which incorporates a proprietary library of adeno-associated viral vectors and an innovative delivery method. The firm's leading experimental therapy is AK-OTOF, a gene therapy designed to treat hearing impairment caused by mutations in the OTOF gene. Additionally, Akouos is advancing AK-CLRN1 for the auditory symptoms linked to Usher syndrome type 3A (USH3A), and AK-antiVEGF for addressing vestibular schwannoma. The company's comprehensive genetic platform further addresses hearing loss related to genes essential for supporting cell function. Founded in 2016, Akouos, Inc. is headquartered in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Akouos, Inc. (AKUS)
Akouos, Inc. is a company dedicated to precise genetic medicine, developing gene therapies with the aim of restoring, enhancing, and safeguarding individuals' natural auditory function. Central to its strategy is an advanced genetic medicine platform, which incorporates a proprietary library of adeno-associated viral vectors and an innovative delivery method. The firm's leading experimental therapy is AK-OTOF, a gene therapy designed to treat hearing impairment caused by mutations in the OTOF gene. Additionally, Akouos is advancing AK-CLRN1 for the auditory symptoms linked to Usher syndrome type 3A (USH3A), and AK-antiVEGF for addressing vestibular schwannoma. The company's comprehensive genetic platform further addresses hearing loss related to genes essential for supporting cell function. Founded in 2016, Akouos, Inc. is headquartered in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free